Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbbreviations
Ver el documento1. Summary
Abrir esta carpeta y ver su contenido2. Introduction
Abrir esta carpeta y ver su contenido3. Study design and methods
Ver el documento4. Results
Abrir esta carpeta y ver su contenido5. Discussion
Abrir esta carpeta y ver su contenido6. Conclusions and recommendations
Ver el documentoReferences
Cerrar esta carpetaAnnexes
Cerrar esta carpetaAnnex 1: Detailed results for each drug
Ver el documento1.1 Amoxycillin capsules
Ver el documento1.2 Ampicillin capsules
Ver el documento1.3 Acetylsalicylic acid tablets
Ver el documento1.4 Doxycycline capsules
Ver el documento1.5 Ferrous sulfate tablets
Ver el documento1.6 Phenoxymethylpenicillin tablets
Ver el documento1.7 Tetracycline capsules
Ver el documento1.8 Retinol tablets
Ver el documento1.9 Epinephrine injection
Ver el documento1.10 Ampicillin injection
Ver el documento1.11 Benzylpenicillin injection
Ver el documento1.12 Ergometrine injection
Ver el documento1.13 Procaine penicillin injection
Ver el documentoAnnex 2: Validation of laboratory results
 

1.1 Amoxycillin capsules

SHELF LIFE

Manufacturer A: 2-3 years

ASSAY METHOD

Spectrophotometric method, BP 1988, p. 625 Contents of 20 capsules mixed; measured three times; mean taken.

ASSAY LIMITS

92.5 - 110% (BP)

SAMPLES OBTAINED

Manufacturer A

GMS samples

no.

%

Total

6

100

Harare

2

33

Bulawayo

4

67

Facility samples

no.

%

Total

25

100

Age > 50% SLife

23

92

Facility type = PCH

0

0

Climate = hot

13

52

Transport = slow

17

68

Longitudinal series

   

Total

5

100

SUMMARY ASSAY RESULTS

GMS samples

Manufacturer A

Mean age (mths)

 

2.7

Mean assay

 

96.2%

95% CL

93.8 - 98.5%

No, and % fail

0

0%

Facility samples

Manufacturer A

Mean age (mths)

 

17.1

Mean assay

 

98.8%

95% CL

97.8 - 99.8%

No, and % fail

0

0%

Longitudinal series

at manufacturer

at GMS

at facility

Mean age (mths)

0

12.6

20.1

Mean assay

98.1%

96.9

99.2

95% CL

96.9 - 99.4%

94.6 - 99.1%

96.7-101.7%

No. and % fail

0

0%

0

0%

0

0%

 

Mean interval (mths)

7.6

 

Mean loss (-) or gain (+)

+2.4%

 

95% CL for loss/gain

+0.1 to +4.7%


Figure 1 - Results of facility samples

Findings:

a) Four of 29 facility samples (14%) were expired; these results were excluded,
b) All six GMS samples were within assay limits (mean 96.2%).
c) All 25 facility samples were within assay limits (mean 98.8%).
d) Hospital-only drug with slow turnover: mean facility storage time: 6.4 months (0-15 months).
e) 23 of the facility samples (92%) had expended more than half their shelf life.
f) No loss of potency was found in five GMS/facility sample pairs.
g) No initial quality problem was seen.
h) No sign of instability, even in the late part of shelf life.
i) Hour expired samples had a mean assay of 100.6% at mean age 28.0 months.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013